- Login
- Manage Portfolio
- Post a StockTalk
- Write an Instablog
- Get Daily Email Alert
-
Seeking Alpha
|
|
| 52wk high: | |
| 52wk low: | |
| EPS: | |
| PE: | |
| Dividend: | |
| Yield: | |
| Market Cap: | |
| Exchange: | |
Articles on BioCryst Pharmaceuticals Inc. (BCRX)
by latest | most commented
-
Big Lineup of Healthcare Stocks Crack the Russell 3000 Index
-
Companies Involved in the Treatment of Swine Flu
-
A Biotech Triple Play: Dendreon, BioCryst and Arena
-
How the U.S. Profits From Swine Flu
-
Swine Flu: A Follow-Up on 'Trading the Hype'
-
Swine Flu: Trade Smartly, Beware the Hype
-
Swine Flu Stock Watchlist
-
5 Potential Pandemic Shorts
-
Tuesday's Options Recap
-
The Swine Flu Effect
-
Beneficiaries and Losers from the Swine Flu Scare
-
Short Term Swine Flu Trades
-
Novavax: Swine Flu Vaccine Maker's Shares Surge
-
Weekly CFO Buys List: Flagstar Bancorp, Royal Caribbean, Greenbrier Companies, BioCryst Pharma, Buckeye Tech
-
BioCryst Management Needs to Earn Investors' Trust
-
Cancer Stocks: Lagging Again
-
Cancer Stocks: The Bleeding Slows
-
Cancer Stocks Hammered Once Again
-
Cancer Stocks Slide Again
-
Cancer Stocks Plunge Following ASCO Meeting
-
Cancer Stocks Soar With Annual ASCO Meeting
-
Cancer Stocks on the Go: Winners and Losers
-
Biotech Day In Review: Regeneron Up On AMD Data
-
Biotech Day in Review: Novartis Gets Approval for Hypertensive Drug Tekturna
-
Biotech Day in Review: ImClone Chooses to Go It Alone
-
Biotech Stocks Day-In-Review: Amgen Disappoints After The Bell
-
Biotech Stocks Day-in-Review: BioCryst Begins Pivotal Trial of Fodosine
-
Biotech Indices Mixed as AMEX Gains, Nasdaq Slips
-
Biotech Stocks Day-in-Review: BioCryst Gets Flu Drug Support
-
BioCryst Receives Fast-Track Status for Peramivir, But Does It Justify The Stock's Appreciation? (BCRX)
-
The President's Avian Flu Plan: Boon or Bust for the Speculators? (BCRX, GILD, QDEL, RHHBY)
-
BioCryst and Avian Flu: Underappreciated Call Option or Just Overhyped? (BCRX)
-
Stocks Covered by The Biotech Stock Blog